drugset / Trial / NCT03581942
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of combined use of the study drugs, copanlisib and ibrutinib, in people with PCNSL.
Timeline
- Start
- 2018-08-23
- Primary completion
- 2026-02-05
- Completion
- 2026-02-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Copanlisib | Small molecule | 45 mg | — |
| Subject | Copanlisib | Small molecule | 60 mg | — |
| Subject | Ibrutinib | Small molecule | 560 mg | — |
| Subject | Ibrutinib | Small molecule | 840 mg | — |